CCR2 | Chemokine receptors | IUPHAR/BPS Guide to PHARMACOLOGY

CCR2

Target id: 59

Nomenclature: CCR2

Family: Chemokine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     CCR2 has curated GtoImmuPdb data

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 374 3p21 CCR2 C-C motif chemokine receptor 2 17,64
Mouse 7 373 9 F Ccr2 chemokine (C-C motif) receptor 2 42,49
Rat 7 373 8q32 Ccr2 C-C motif chemokine receptor 2 7,37
Previous and Unofficial Names
MCP-1 receptor [17,29] | CC CKR2 | CKR2 | CD192 | chemokine receptor CCR2 | CCR2A | CCR2B | chemokine (C-C motif) receptor 2
Database Links
Specialist databases
GPCRDB ccr2_human (Hs), ccr2_mouse (Mm), ccr2_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists (BMS-681 and CCR2-RA-[R] respectively)
PDB Id:  5T1A
Ligand:  BMS-681
Resolution:  2.81Å
Species:  Human
References:  88
Natural/Endogenous Ligands
CCL7 {Sp: Human}
CCL13 {Sp: Human}
CCL2 {Sp: Human}
CCL8 {Sp: Human}
CCL16 {Sp: Human}
CCL11 {Sp: Human}
CCL26 {Sp: Human}
CCL2 {Sp: Mouse}
CCL7 {Sp: Mouse}
CCL8 {Sp: Mouse}
CCL11 {Sp: Mouse}
CCL2 {Sp: Rat}
CCL7 {Sp: Rat}
CCL11 {Sp: Rat}
Comments: CCL2 is the principal endogenous agonist

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
CCL2 {Sp: Human} Hs Full agonist 9.3 – 10.2 pIC50 21,47,51,55,76
pIC50 9.3 – 10.2 [21,47,51,55,76]
CCL13 {Sp: Human} Hs Full agonist 8.6 – 8.7 pIC50 47,76
pIC50 8.6 – 8.7 [47,76]
CCL8 {Sp: Human} Hs Full agonist 8.6 pIC50 47
pIC50 8.6 [47]
CCL7 {Sp: Human} Hs Full agonist 8.4 – 8.7 pIC50 21,47,76
pIC50 8.4 – 8.7 [21,47,76]
HIV-Tat Hs Full agonist 8.3 pIC50 3
pIC50 8.3 [3]
CCL11 {Sp: Human} Hs Partial agonist 7.1 – 7.7 pIC50 47,55
pIC50 7.1 – 7.7 [47,55]
vCCL4 Hs Full agonist 7.1 pIC50 47
pIC50 7.1 [47]
CCL16 {Sp: Human} Hs Full agonist - -
Agonist Comments
It has been shown that CCL12 is a ligand for the CCR2 receptor [66].
vCCL4 is the secreted protein product of the U83 gene from the human herpesvirus 6 [47].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
TAK-779 Hs Antagonist 7.2 – 8.2 pKi 5,9
pKi 8.2 [5,9]
pKi 7.2 [9]
SB-282241 Hs Antagonist 7.0 pKi 9
pKi 7.0 [9]
RS-504393 Hs Antagonist 6.7 pKi 9
pKi 6.7 [9]
Teijin-lead_cmp_5 Hs Antagonist 6.5 pKi 9
pKi 6.5 [9]
BMS-681 Hs Antagonist 9.1 pIC50 16
pIC50 9.1 (IC50 7x10-10 M) [16]
viral macrophage inflammatory protein-II Hs Antagonist 9.1 pIC50 41
pIC50 9.1 [41]
MC148R Hs Antagonist 8.8 pIC50 23
pIC50 8.8 [23]
CCL26 {Sp: Human} Hs Antagonist 8.5 pIC50 55
pIC50 8.5 [55]
RS-136270 Hs Antagonist 8.5 pIC50 51
pIC50 8.5 [51]
INCB3284 Hs Antagonist 8.4 pIC50 82
pIC50 8.4 (IC50 3.7x10-9 M) [82]
PF-04634817 Hs Antagonist 8.4 pIC50 33
pIC50 8.4 (IC50 3.68x10-9 M) [33]
Description: Whole cell binding assay measuring displacement of [125I]MCP-1 from CCR2 by PF-04634817 in human peripheral blood mononuclear cells.
MK-0812 Monkey Antagonist 8.4 pIC50 80
pIC50 8.4 (IC50 4.5x10-9 M) [80]
Description: Measuring inhibition of [125]I-MCP-1 binding by MK-0812 on isolated monocytes.
INCB8761 Hs Antagonist 8.3 pIC50 83
pIC50 8.3 (IC50 5.2x10-9 M) [83]
INCB3344 Mm Antagonist 8.0 pIC50 14
pIC50 8.0 [14]
RS-102895 Hs Antagonist 6.3 pIC50 51
pIC50 6.3 [51]
CCL24 {Sp: Human} Hs Antagonist 6.2 pIC50 55
pIC50 6.2 [55]
View species-specific antagonist tables
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
AZD2423 Hs Negative 8.6 pIC50 22
pIC50 8.6 (IC50 2.6x10-9 M) [22]
CCR2-RA-[R] Hs Antagonist >5.3 pIC50 24,89
pIC50 >5.3 (IC50 <5x10-6 M) [24,89]
Description: Antagonism of 125I-MCP-1 binding to THP-1 cells
Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
plozalizumab Hs Binding 9.7 pEC50 45
pEC50 9.7 (EC50 1.9x10-10 M) [45]
Description: Calculated from ng/ml based on a mol weight of ~150kDa.
Immunopharmacology Comments
CCR2 is one of more than 20 distinct chemokine receptors expressed in human leukocytes. Chemokines primarily act to promote leukocyte chemotaxis to sites of inflammation. CCR2 is discussed in relation to immuno-oncology in [2].
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 12 GO processes
GO:0002407 dendritic cell chemotaxis TAS
GO:0006954 inflammatory response TAS
GO:0010820 positive regulation of T cell chemotaxis ISS
GO:0035705 T-helper 17 cell chemotaxis ISS
GO:0043310 negative regulation of eosinophil degranulation ISS
GO:0050729 positive regulation of inflammatory response ISS
GO:0090026 positive regulation of monocyte chemotaxis IDA
GO:2000439 positive regulation of monocyte extravasation ISS
GO:2000451 positive regulation of CD8-positive, alpha-beta T cell extravasation ISS
click arrow to show/hide IEA associations
GO:0002548 monocyte chemotaxis IEA
GO:0097350 neutrophil clearance IEA
GO:1903238 positive regulation of leukocyte tethering or rolling IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 3 GO processes
GO:0002827 positive regulation of T-helper 1 type immune response ISS
GO:0046641 positive regulation of alpha-beta T cell proliferation ISS
GO:0050870 positive regulation of T cell activation ISS
Immuno Process:  Antigen presentation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0097350 neutrophil clearance IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes
GO:0002827 positive regulation of T-helper 1 type immune response ISS
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0030097 hemopoiesis IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 13 GO processes
GO:0002827 positive regulation of T-helper 1 type immune response ISS
GO:0002829 negative regulation of type 2 immune response ISS
GO:0010820 positive regulation of T cell chemotaxis ISS
GO:0043310 negative regulation of eosinophil degranulation ISS
GO:0046641 positive regulation of alpha-beta T cell proliferation ISS
GO:0050729 positive regulation of inflammatory response ISS
GO:0050870 positive regulation of T cell activation ISS
GO:0090026 positive regulation of monocyte chemotaxis IDA
GO:0090265 positive regulation of immune complex clearance by monocytes and macrophages ISS
GO:2000439 positive regulation of monocyte extravasation ISS
GO:2000451 positive regulation of CD8-positive, alpha-beta T cell extravasation ISS
click arrow to show/hide IEA associations
GO:0097350 neutrophil clearance IEA
GO:1903238 positive regulation of leukocyte tethering or rolling IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 8 GO processes
GO:0004950 chemokine receptor activity TAS
GO:0010574 regulation of vascular endothelial growth factor production ISS
GO:0019221 cytokine-mediated signaling pathway IDA
GO:0032729 positive regulation of interferon-gamma production ISS
GO:0032743 positive regulation of interleukin-2 production ISS
GO:0042535 positive regulation of tumor necrosis factor biosynthetic process ISS
GO:0070098 chemokine-mediated signaling pathway ISS
click arrow to show/hide IEA associations
GO:0016493 C-C chemokine receptor activity IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 11 GO processes
GO:0002407 dendritic cell chemotaxis TAS
GO:0010820 positive regulation of T cell chemotaxis ISS
GO:0035705 T-helper 17 cell chemotaxis ISS
GO:0046641 positive regulation of alpha-beta T cell proliferation ISS
GO:0050870 positive regulation of T cell activation ISS
GO:0090026 positive regulation of monocyte chemotaxis IDA
GO:2000439 positive regulation of monocyte extravasation ISS
GO:2000451 positive regulation of CD8-positive, alpha-beta T cell extravasation ISS
click arrow to show/hide IEA associations
GO:0002548 monocyte chemotaxis IEA
GO:0061756 leukocyte adhesion to vascular endothelial cell IEA
GO:1903238 positive regulation of leukocyte tethering or rolling IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 3 GO processes
GO:0043310 negative regulation of eosinophil degranulation ISS
GO:0046641 positive regulation of alpha-beta T cell proliferation ISS
GO:0050870 positive regulation of T cell activation ISS
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family
References:  38
Tissue Distribution
CD4+ T lymphocytes.
Species:  Human
Technique:  Flow cytometry.
References:  40
Basophils.
Species:  Human
Technique:  Flow cytometry and Northern blotting.
References:  76
Tonsil B lymphocytes.
Species:  Human
Technique:  RT-PCR.
References:  20
Basophils.
Species:  Human
Technique:  RT-PCR and flow cytometry.
References:  34
Blood dendritic cells.
Species:  Human
Technique:  RT-PCR.
References:  4
Microvascular endothelial cells.
Species:  Human
Technique:  RNase protection assay.
References:  63
Vascular smooth muscle cells.
Species:  Human
Technique:  RT-PCR.
References:  29
Monocytes.
Species:  Mouse
Technique: 
References:  49
Microglia.
Species:  Rat
Technique:  Northern blotting.
References:  37
Brain: anterior and dorsal olfactory nuclei, cerebral cortex, basal forebrain, basal ganglia, amygdala, hippocampus, thalamus, hypothalamus.
Species:  Rat
Technique:  Immunohistochemistry.
References:  6
Lung, spleen, kidney, thymus, macrophages.
Species:  Rat
Technique:  RNase protection assay.
References:  37
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of Ca2+ levels in human vascular smooth muscle cells (VSMCs) endogenously expressing the CCR2 receptor.
Species:  Human
Tissue:  VSMCs.
Response measured:  Increase in Ca2+ concentration.
References:  29
Measurement of Ca2+ levels in human monocytic THP-1 and MonoMac 6 cells endogenously expressing the CCR2 receptor.
Species:  Human
Tissue:  Monocytic cell lines THP-1 and MonoMac 6.
Response measured:  Ca2+ mobilisation.
References:  17
Measurement of Ca2+ levels in Xenopus laevis oocytes transfected with the human CCR2 receptor.
Species:  Human
Tissue:  Xenopus laevis oocytes.
Response measured:  Ca2+ mobilisation.
References:  17
Measurement of cAMP levels in HEK 293 cells transfected with the human CCR2 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  36
Measurement of chemotaxis of the human monocyte cell line THP-1 endogenously expressing the CCR2 receptor.
Species:  Human
Tissue:  THP-1 cells.
Response measured:  Chemotaxis.
References:  36
Detection of HIV-1 p24 antigen in human peripheral blood mononuclear cells (PBMCs) endogenously expressing the CCR2 receptor.
Species:  Human
Tissue:  PBMCs.
Response measured:  HIV-1 entry.
References:  26
Measurement of MAP kinase cascade activity in HEK 293 cells transfected with the CCR2 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  ERK activation.
References:  38
Physiological Functions
HIV-1 coreceptor.
Species:  Human
Tissue:  PBMCs.
References:  26
Chemotaxis.
Species:  Mouse
Tissue:  Leukocytes.
References:  12
Macrophage recruitment.
Species:  Rat
Tissue:  In vivo (kidney).
References:  87
Macrophage recruitment.
Species:  Mouse
Tissue:  In vivo.
References:  32,43-44,56,78
Dendritic cell migration and localisation.
Species:  Mouse
Tissue:  In vivo.
References:  67
Atherogenesis.
Species:  Mouse
Tissue:  In vivo.
References:  13,28
Neovascularisation (angiogenesis).
Species:  Rat
Tissue:  Aorta.
References:  62
Physiological Consequences of Altering Gene Expression
Myeloid progenitor cells from the bone marrow of CCR2 receptor knockout mice exhibit enhanced cell cycling and apoptosis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  60
CCR2 receptor knockout mice with cockroach allergen-induced airway inflammation were less susceptable to hyperreactivity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  15
CCR2 receptor knockout mice exhibit resistance to experimental autoimmune encephalomyelitis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  25,35
CCR2 receptor knockout mice suffering from an injured nervous system exhibit impaired macrophage/monocyte recruitment and delayed myelin removal.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  48,69
Following infection with a bacteria/virus/yeast/parasite, CCR2 receptor knockout mice exhibit defective macrophage/monocyte recruitment, enhanced accumulation of neutrophils and eosinophils, and decreased INF-γ production. They have reduced defence against infection and often develop fewer and smaller granulomas compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  10,12,30,32,43-44,56,61,68,75,78
CCR2 receptor knockout mice exhibit impaired macrophage recruitment and slower LDL cholesterol clearance.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  71
CCR2 receptor knockout mice exhibit impaired inflammatory and neuropathic pain states.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1
CCR2 receptor knockout mice exhibit reduced renal interstitial fibrosis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  39
CCR2 receptor knockout mice exhibit impaired lung dendritic cell activation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  18
CCR2 receptor knockout mice exhibit a reduction in the size and number of induced liver tumours, decreased neovascularisation, decreased matrix metalloproteinase 2 expression and a reduction in the recruitment of macrophages and hepatic stellate cells.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  85
CCR2 receptor knockout mice exhibit lower preference for alcohol and consumption of lower amounts of alcohol compared to wild-type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11
CCR2 receptor knockout mice exhibit a reduction in food intake, reduced development of obesity in mice fed on a high-fat diet, a decrease in macrophage recruitment and inflammation in adipose tissue, as well as improved systemic glucose homeostasis and insulin sensitivity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  79
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6J
MGI:106185  MP:0004883 abnormal blood vessel healing PMID: 12065319 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0010119 abnormal bone mineral density PMID: 19330010 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0005239 abnormal Bruch membrane morphology PMID: 14566334 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0000130 abnormal cancellous bone morphology PMID: 19330010 
Ccr2tm1Blck Ccr2tm1Blck/Ccr2tm1Blck
B6.129P2-Ccr2
MGI:106185  MP:0009858 abnormal cellular extravasation PMID: 16275892 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd
MGI:106185  MP:0008722 abnormal chemokine secretion PMID: 19641140 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005278 abnormal cholesterol homeostasis PMID: 12504109 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0006238 abnormal choriocapillaris morphology PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0005098 abnormal choroid morphology PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0002805 abnormal conditioned taste aversion behavior PMID: 16105698 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0003009 abnormal cytokine secretion PMID: 10843684 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0002723 abnormal immune serum protein physiology PMID: 10438957 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0002722 abnormal immune system organ morphology PMID: 16267157 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0008750 abnormal interferon level PMID: 16267157 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005362 abnormal Langerhans cell physiology PMID: 16444257 
Ccr2tm1Blck Ccr2tm1Blck/Ccr2tm1Blck
B6.129P2-Ccr2
MGI:106185  MP:0003628 abnormal leukocyte adhesion PMID: 16275892 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0003156 abnormal leukocyte migration PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0002442 abnormal leukocyte physiology PMID: 17257744 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * BALB/c
MGI:106185  MP:0002442 abnormal leukocyte physiology PMID: 18843253 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2
MGI:106185  MP:0003627 abnormal leukocyte tethering or rolling PMID: 19357362 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0002118 abnormal lipid homeostasis PMID: 12504109 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0000717 abnormal lymphocyte cell number PMID: 16267157 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005495 abnormal macrophage recruitment PMID: 9366570 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0003691 abnormal microglial cell physiology PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0003691 abnormal microglial cell physiology PMID: 17351623 
Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2tm1Ifc,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0003691 abnormal microglial cell physiology PMID: 17351623 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae
MGI:106185  MP:0002620 abnormal monocyte morphology PMID: 17364026 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0004983 abnormal osteoclast cell number PMID: 19330010 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0008396 abnormal osteoclast differentiation PMID: 19330010 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0001541 abnormal osteoclast physiology PMID: 19330010 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0005325 abnormal renal glomerulus morphology PMID: 16267157 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0002703 abnormal renal tubule morphology PMID: 16267157 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0005201 abnormal retinal pigment epithelium morphology PMID: 14566334 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0000689 abnormal spleen morphology PMID: 9362535 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0008752 abnormal tumor necrosis factor level PMID: 16267157 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0002871 albuminuria PMID: 16267157 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0002570 alcohol aversion PMID: 16105698 
Ccl2tm1Rol|Ccr2tm1Mae Ccl2tm1Rol/Ccl2tm1Rol,Ccr2tm1Mae/Ccr2tm1Mae
B6.129-Ccr2 Ccl2
MGI:106185  MGI:98259  MP:0002570 alcohol aversion PMID: 16105698 
Ccl2tm1Rol|Ccr2tm1Mae Ccl2tm1Rol/Ccl2tm1Rol,Ccr2tm1Mae/Ccr2tm1Mae
B6.129-Ccr2 Ccl2
MGI:106185  MGI:98259  MP:0001987 alcohol preference PMID: 16105698 
Ccr2tm1Blck Ccr2tm1Blck/Ccr2tm1Blck
B6.129P2-Ccr2
MGI:106185  MP:0000343 altered response to myocardial infarction PMID: 16275892 
Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2tm1Ifc,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0003329 amyloid beta deposits PMID: 17351623 
Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2tm1Ifc,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0000604 amyloidosis PMID: 17351623 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0005546 choroidal neovascularization PMID: 14566334 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0005087 decreased acute inflammation PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0002335 decreased airway responsiveness PMID: 10438957 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0003546 decreased alcohol consumption PMID: 16105698 
Ccl2tm1Rol|Ccr2tm1Mae Ccl2tm1Rol/Ccl2tm1Rol,Ccr2tm1Mae/Ccr2tm1Mae
B6.129-Ccr2 Ccl2
MGI:106185  MGI:98259  MP:0003546 decreased alcohol consumption PMID: 16105698 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0008075 decreased CD4-positive T cell number PMID: 10843684 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * BALB/c
MGI:106185  MP:0005554 decreased circulating creatinine level PMID: 18843253 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008813 decreased common myeloid progenitor cell number PMID: 9366570 
Ccl2tm1Rol|Ccr2tm1Mae Ccl2tm1Rol/Ccl2tm1Rol,Ccr2tm1Mae/Ccr2tm1Mae
B6.129-Ccr2 Ccl2
MGI:106185  MGI:98259  MP:0003912 decreased drinking behavior PMID: 16105698 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0001876 decreased inflammatory response PMID: 10843684 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0001876 decreased inflammatory response PMID: 9366570 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0008567 decreased interferon-gamma secretion PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008567 decreased interferon-gamma secretion PMID: 11015448  9366570 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008688 decreased interleukin-2 secretion PMID: 9366570 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008706 decreased interleukin-6 secretion PMID: 11015448 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0003884 decreased macrophage cell number PMID: 14566334 
Apoetm1Unc|Ccr2tm1Ifc|Cx3cl1tm1Lira Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc,Cx3cl1tm1Lira/Cx3cl1tm1Lira
B6.Cg-Apoe Cx3cl1 Ccr2
MGI:106185  MGI:1097153  MGI:88057  MP:0000223 decreased monocyte cell number PMID: 18165355 
Apoetm1Unc|Ccr2tm1Ifc Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc
B6.Cg-Apoe Ccr2
MGI:106185  MGI:88057  MP:0000223 decreased monocyte cell number PMID: 18165355 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * BALB/c
MGI:106185  MP:0000222 decreased neutrophil cell number PMID: 18843253 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0004985 decreased osteoclast cell number PMID: 19330010 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0009335 decreased splenocyte proliferation PMID: 11015448 
Apoetm1Unc|Ccr2tm1Ifc Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
MGI:106185  MGI:88057  MP:0005341 decreased susceptibility to atherosclerosis PMID: 9732872 
Apoetm1Unc|Ccr2+|Ccr2tm1Ifc Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
MGI:106185  MGI:88057  MP:0005341 decreased susceptibility to atherosclerosis PMID: 9732872 
Apoetm1Unc|Ccr2tm1Ifc|Cx3cl1tm1Lira Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc,Cx3cl1tm1Lira/Cx3cl1tm1Lira
B6.Cg-Apoe Cx3cl1 Ccr2
MGI:106185  MGI:1097153  MGI:88057  MP:0005341 decreased susceptibility to atherosclerosis PMID: 18165355 
Apoetm1Unc|Ccr2tm1Ifc Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc
B6.Cg-Apoe Ccr2
MGI:106185  MGI:88057  MP:0005341 decreased susceptibility to atherosclerosis PMID: 18165355 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0009878 decreased susceptibility to bone fracture PMID: 19330010 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0004800 decreased susceptibility to experimental autoimmune encephalomyelitis PMID: 11015448 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2
MGI:106185  MP:0008539 decreased susceptibility to induced colitis PMID: 20483766 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * BALB/c
MGI:106185  MP:0004042 decreased susceptibility to kidney reperfusion injury PMID: 18843253 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005597 decreased susceptibility to type I hypersensitivity reaction PMID: 10438957 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005095 decreased T cell proliferation PMID: 11015448 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0003447 decreased tumor growth/size PMID: 17257744 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0005036 diarrhea PMID: 10843684 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0000599 enlarged liver PMID: 9362535 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0000702 enlarged lymph nodes PMID: 16267157 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0000691 enlarged spleen PMID: 9362535 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0000691 enlarged spleen PMID: 16267157 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0002743 glomerulonephritis PMID: 16267157 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0001654 hepatic necrosis PMID: 10751350 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0003799 impaired macrophage migration PMID: 17351623  9366570 
Ccr2+|Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2+
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0003799 impaired macrophage migration PMID: 17351623 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0005496 impaired macrophage recruitment PMID: 9362535 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd
MGI:106185  MP:0005496 impaired macrophage recruitment PMID: 19641140 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0005496 impaired macrophage recruitment PMID: 12504109 
Apoetm1Unc|Ccr2tm1Ifc Apoetm1Unc/Apoetm1Unc,Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
MGI:106185  MGI:88057  MP:0005496 impaired macrophage recruitment PMID: 9732872 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * BALB/c
MGI:106185  MP:0005496 impaired macrophage recruitment PMID: 18843253 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0003545 increased alcohol consumption PMID: 16105698 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0005014 increased B cell number PMID: 10843684 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0009347 increased cancellous bone thickness PMID: 19330010 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0008078 increased CD8-positive T cell number PMID: 10843684 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0002941 increased circulating alanine transaminase level PMID: 10751350 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0003911 increased drinking behavior PMID: 16105698 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0005011 increased eosinophil cell number PMID: 9362535 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0003887 increased hepatocyte apoptosis PMID: 10751350 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0002493 increased IgG level PMID: 14566334 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008566 increased interferon-gamma secretion PMID: 10751350 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008873 increased physiological sensitivity to xenobiotic PMID: 10751350 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0002412 increased susceptibility to bacterial infection PMID: 9362535 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0008537 increased susceptibility to induced colitis PMID: 10843684 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0002418 increased susceptibility to viral infection PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
B6.129S4-Ccr2/J
MGI:106185  MP:0009791 increased susceptibility to viral infection induced morbidity/mortality PMID: 11591787 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0008560 increased tumor necrosis factor secretion PMID: 10751350 
Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2tm1Ifc,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0001915 intracranial hemorrhage PMID: 17351623 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0001859 kidney inflammation PMID: 16267157 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0008842 lipofuscinosis PMID: 14566334 
Ccr2tm1Ifc Ccr2tm1Ifc/Ccr2tm1Ifc
involves: 129S4/SvJae * C57BL/6
MGI:106185  MP:0003888 liver hemorrhage PMID: 10751350 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0001860 liver inflammation PMID: 9362535 
Ccr2tm1Brv Ccr2tm1Brv/Ccr2tm1Brv
involves: 129S1/Sv * ICR
MGI:106185  MP:0001655 multifocal hepatic necrosis PMID: 9362535 
Ccr2tm1Blck|Faslpr Ccr2tm1Blck/Ccr2tm1Blck,Faslpr/Faslpr
MRL.Cg-Ccr2 Fas
MGI:106185  MGI:95484  MP:0002083 premature death PMID: 16267157 
Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2tm1Ifc,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0002083 premature death PMID: 17351623 
Ccr2+|Ccr2tm1Ifc|Tg(APPSWE)2576Kha Ccr2tm1Ifc/Ccr2+,Tg(APPSWE)2576Kha/0
involves: 129S4/SvJae * C57BL/6 * SJL
MGI:106185  MGI:2385632  MP:0002083 premature death PMID: 17351623 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0001326 retinal degeneration PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0006187 retinal deposits PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0008518 retinal outer nuclear layer degeneration PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
B6.129P2-Ccr2
MGI:106185  MP:0008450 retinal photoreceptor degeneration PMID: 14566334 
Ccr2tm1Mae Ccr2tm1Mae/Ccr2tm1Mae
involves: 129P2/OlaHsd * C57BL/6J
MGI:106185  MP:0001263 weight loss PMID: 10843684 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Human immunodeficiency virus type 1, susceptibility to
Synonyms: Human immunodeficiency virus infectious disease [Disease Ontology: DOID:526]
Disease Ontology: DOID:526
OMIM: 609423
Orphanet: ORPHA319269
Biologically Significant Variants
Type:  Splice variants
Species:  Human
Description:  Two splice variants of the human CCR2 gene have been identified, CCR2-B being the more predominant form of the receptor, and CCR2-A having a shorter C-terminus with impaired receptor trafficking to the cell surface.
References:  8,57,65,74,81
Type:  Single nucleotide polymorphism
Species:  Human
Description:  A Val64 -> Ile polymorphism in the CCR2 gene has been identified in humans. The Ile substituted CCR2-A receptor variant is thought to be associated with a delay in disease progression from HIV-1 to AIDS perhaps by interfering with the cell surface expression of the CCR5 receptor.
Amino acid change:  V64I
References:  46,52-53,57,70,72
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may have a protective effect on the development of Alzheimer's disease.
Amino acid change:  V64I
References:  27
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be associated with an reduced loss of bone mineral density in middle-aged men and postmenopausal women.
Amino acid change:  V64I
References:  84
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be linked to the development of breast cancer.
Amino acid change:  V64I
References:  86
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be linked to increased risk of myocardial infarction and heart failure.
Amino acid change:  V64I
References:  54,59
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be associated with a reduced risk of coronary artery disease.
Amino acid change:  V64I
References:  73,77
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may provide protection in mother-to-infant HIV-1 transmission.
Amino acid change:  V64I
References:  50
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be associated with a lower risk for the development of sarcoidosis.
Amino acid change:  V64I
References:  31,58
Type:  Single nucleotide polymorphism
Species:  Human
Description:  The Val64 -> Ile polymorphism may be linked to a decreased risk of developing invasive cervical cancer.
Amino acid change:  V64I
References:  19

References

Show »

1. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ. (2003) Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A, 100: 7947-7952. [PMID:12808141]

2. Adams JL, Smothers J, Srinivasan R, Hoos A. (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov, 14 (9): 603-22. [PMID:26228631]

3. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G, Rabin RL, Farber JM, Noonan DM. (1998) HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U.S.A., 95: 13153-13158. [PMID:9789057]

4. Ayehunie S, Garcia-Zepeda EA, Hoxie JA, Horuk R, Kupper TS, Luster AD, Ruprecht RM. (1997) Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood, 90: 1379-1386. [PMID:9269754]

5. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A., 96: 5698-5703. [PMID:10318947]

6. Banisadr G, Gosselin RD, Mechighel P, Rostene W, Kitabgi P, Mélik Parsadaniantz S. (2005) Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J Comp Neurol, 492: 178-192. [PMID:16196033]

7. Banisadr G, Quéraud-Lesaux F, Boutterin MC, Pélaprat D, Zalc B, Rostene W, Haour F, Parsadaniantz SM. (2002) Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem, 81: 257-269. [PMID:12064472]

8. Bartoli C, Civatte M, Pellissier JF, Figarella-Branger D. (2001) CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies. Acta Neuropathol (Berl), 102: 385-392. [PMID:11603815]

9. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, Kaur R, Moores KE, Shillito H, Willetts J, Witherington J. (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem, 46: 4070-4086. [PMID:12954060]

10. Blease K, Mehrad B, Standiford TJ, Lukacs NW, Gosling J, Boring L, Charo IF, Kunkel SL, Hogaboam CM. (2000) Enhanced pulmonary allergic responses to Aspergillus in CCR2-/- mice. J Immunol, 165: 2603-2611. [PMID:10946288]

11. Blednov YA, Bergeson SE, Walker D, Ferreira VM, Kuziel WA, Harris RA. (2005) Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol. Behav Brain Res, 165: 110-125. [PMID:16105698]

12. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest., 100: 2552-2561. [PMID:9366570]

13. Boring L, Gosling J, Cleary M, Charo IF. (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 394: 894-897. [PMID:9732872]

14. Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, Collier P, Stow M, Gu X, Baribaud F, Shin N, Thomas B, Burn T, Hollis G, Yeleswaram S, Solomon K, Friedman S, Wang A, Xue CB, Newton RC, Scherle P, Vaddi K. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol, 175: 5370-5378. [PMID:16210643]

15. Campbell EM, Charo IF, Kunkel SL, Strieter RM, Boring L, Gosling J, Lukacs NW. (1999) Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J. Immunol., 163: 2160-2167. [PMID:10438957]

16. Carter PH, Brown GD, Cherney RJ, Batt DG, Chen J, Clark CM, Cvijic ME, Duncia JV, Ko SS, Mandlekar S et al.. (2015) Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5. ACS Med Chem Lett, 6 (4): 439-44. [PMID:25893046]

17. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A, 91: 2752-2756. [PMID:8146186]

18. Chiu BC, Freeman CM, Stolberg VR, Hu JS, Zeibecoglou K, Lu B, Gerard C, Charo IF, Lira SA, Chensue SW. (2004) Impaired lung dendritic cell activation in CCR2 knockout mice. Am J Pathol, 165: 1199-1209. [PMID:15466386]

19. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, Medeiros R. (2005) Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol, 96: 760-764. [PMID:15721423]

20. Corcione A, Tortolina G, Bonecchi R, Battilana N, Taborelli G, Malavasi F, Sozzani S, Ottonello L, Dallegri F, Pistoia V. (2002) Chemotaxis of human tonsil B lymphocytes to CC chemokine receptor (CCR) 1, CCR2 and CCR4 ligands is restricted to non-germinal center cells. Int Immunol, 14: 883-892. [PMID:12147625]

21. Coulin F, Power CA, Alouani S, Peitsch MC, Schroeder JM, Moshizuki M, Clark-Lewis I, Wells TN. (1997) Characterisation of macrophage inflammatory protein-5/human CC cytokine-2, a member of the macrophage-inflammatory-protein family of chemokines. Eur J Biochem, 248: 507-515. [PMID:9346309]

22. Cumming JG. Slideset: CCR2 antagonists for the treatment of neuropathic pain. The discovery and development of AZD2423. Accessed on 28/10/2014. Modified on 28/10/2014. http://www.rsc.org/images/John_Cumming_tcm18-237052.pdf

23. Damon I, Murphy PM, Moss B. (1998) Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Natl. Acad. Sci. U.S.A., 95: 6403-6407. [PMID:9600978]

24. Dasse OA, Evans JL, Zhai H-X, Zou D, Kintigh JT, Chan F, Hamilton K, Hill E, Eckman JB, Higgins PJ et al.. (2007) Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization. Letters in Drug Design & Discovery, 4 (4): 263-271.

25. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. (2000) CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med, 192: 899-905. [PMID:10993920]

26. Frade JM, Llorente M, Mellado M, Alcamí J, Gutierrez-Ramos JC, Zaballos A, Real G, Martínez-A C. (1997) The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. J Clin Invest, 100: 497-502. [PMID:9239395]

27. Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E, Cutter GR, Mariani C, Forloni G, Pettenati C, Baron P, Conti G, Bresolin N, Scarpini E. (2004) CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. J Neurol Sci, 225: 79-83. [PMID:15465089]

28. Guo J, Van Eck M, de Waard V, Maeda N, Benson GM, Groot PH, Van Berkel TJ. (2005) The presence of leukocyte CC-chemokine receptor 2 in CCR2 knockout mice promotes atherogenesis. Biochim Biophys Acta, 1740: 453-459. [PMID:15949714]

29. Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ, Roach AG, Westwick J, Williams RJ. (1998) Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol, 18: 397-403. [PMID:9514408]

30. Held KS, Chen BP, Kuziel WA, Rollins BJ, Lane TE. (2004) Differential roles of CCL2 and CCR2 in host defense to coronavirus infection. Virology, 329: 251-260. [PMID:15518805]

31. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. (1999) The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med, 159: 2021-2023. [PMID:10351956]

32. Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. (2005) Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol, 174: 1549-1556. [PMID:15661915]

33. Hughes RO, Devraj RV, Rogier DJ, Trujillo JI, Turner SR, Huang W. (2012) 3-aminocyclopentanecarboxamides as chemokine receptor agonists. Patent number: US8293903B2. Priority date: 26/11/2008. Publication date: 23/10/2012.

34. Iikura M, Miyamasu M, Yamaguchi M, Kawasaki H, Matsushima K, Kitaura M, Morita Y, Yoshie O, Yamamoto K, Hirai K. (2001) Chemokine receptors in human basophils: inducible expression of functional CXCR4. J Leukoc Biol, 70: 113-120. [PMID:11435493]

35. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med, 192: 1075-1080. [PMID:11015448]

36. Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, Bloom A, Bhakta S, Diehl F, Freedman R, McCarley D, Polsky I, Ping-Tsou A, Kosaka A, Handel TM. (1999) Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry, 38: 16167-16177. [PMID:10587439]

37. Jiang Y, Salafranca MN, Adhikari S, Xia Y, Feng L, Sonntag MK, deFiebre CM, Pennell NA, Streit WJ, Harrison JK. (1998) Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol, 86: 1-12. [PMID:9655467]

38. Jiménez-Sainz MC, Fast B, Mayor F, Aragay AM. (2003) Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol, 64: 773-782. [PMID:12920215]

39. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel WA, Matsushima K, Mukaida N, Yokoyama H. (2004) Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol, 165: 237-246. [PMID:15215179]

40. Kivisäkk P, Trebst C, Lee JC, Tucky BH, Rudick RA, Campbell JJ, Ransohoff RM. (2003) Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals. J Neurovirol, 9: 291-299. [PMID:12775413]

41. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Luttichau HR, Gerstoft J, Clapham PR, Clark-Lewis I, Wells TN, Schwartz TW. (1997) A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science, 277: 1656-1659. [PMID:9287217]

42. Kurihara T, Bravo R. (1996) Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem, 271: 11603-11607. [PMID:8662823]

43. Kurihara T, Warr G, Loy J, Bravo R. (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med., 186: 1757-1762. [PMID:9362535]

44. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N. (1997) Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A, 94: 12053-12058. [PMID:9342361]

45. LaRosa GJ, Horvath C, Newman W, Jones T, O'Brien SH, O'Keefe T. (2004) Humanized anti-CCR2 antibodies and methods of use therefor. Patent number: US6696550 B2. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 23/07/1998. Publication date: 24/02/2004.

46. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martínez-A C, O'Brien SJ, Dean M, Collman RG, Doms RW. (1998) Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol, 72: 7450-7458. [PMID:9696841]

47. Lüttichau HR, Clark-Lewis I, Jensen PØ, Moser C, Gerstoft J, Schwartz TW. (2003) A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6. J Biol Chem, 278: 10928-10933. [PMID:12554737]

48. Ma M, Wei T, Boring L, Charo IF, Ransohoff RM, Jakeman LB. (2002) Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res, 68: 691-702. [PMID:12111830]

49. Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Plachý J, Brühl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlöndorff D. (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol, 166: 4697-4704. [PMID:11254730]

50. Mangano A, Kopka J, Batalla M, Bologna R, Sen L. (2000) Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3'A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr, 23: 52-57. [PMID:10708056]

51. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J, Morgans D, Wilhelm R, Jarnagin K. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem, 275: 25562-25571. [PMID:10770925]

52. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, Rosenberg PS. (2003) Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS, 17: 377-387. [PMID:12556692]

53. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. (2004) A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS, 18: 729-738. [PMID:15075507]

54. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, Hanrath P, Weber C, Zerres K, Hoffmann R. (2003) Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med, 81: 363-367. [PMID:12719858]

55. Parody TR, Stone MJ. (2004) High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells. Cytokine, 27: 38-46. [PMID:15207250]

56. Peters W, Dupuis M, Charo IF. (2000) A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J Immunol, 165: 7072-7077. [PMID:11120836]

57. Petersen DC, Laten A, Zeier MD, Grimwood A, Rensburg EJ, Hayes VM. (2002) Novel mutations and SNPs identified in CCR2 using a new comprehensive denaturing gradient gel electrophoresis assay. Hum Mutat, 20: 253-259. [PMID:12325020]

58. Petrek M, Drábek J, Kolek V, Zlámal J, Welsh KI, Bunce M, Weigl E, Du Bois R. (2000) CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med, 162: 1000-1003. [PMID:10988120]

59. Petrkova J, Cermakova Z, Drábek J, Lukl J, Petrek M. (2003) CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett, 88: 53-55. [PMID:12853162]

60. Reid S, Ritchie A, Boring L, Gosling J, Cooper S, Hangoc G, Charo IF, Broxmeyer HE. (1999) Enhanced myeloid progenitor cell cycling and apoptosis in mice lacking the chemokine receptor, CCR2. Blood, 93: 1524-1533. [PMID:10029580]

61. Robben PM, LaRegina M, Kuziel WA, Sibley LD. (2005) Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J Exp Med, 201: 1761-1769. [PMID:15928200]

62. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood, 96: 34-40. [PMID:10891427]

63. Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, Oppenheim JJ. (2001) Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol, 166: 7571-7578. [PMID:11390513]

64. Samson M, Soularue P, Vassart G, Parmentier M. (1996) The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics, 36: 522-526. [PMID:8884276]

65. Sanders SK, Crean SM, Boxer PA, Kellner D, LaRosa GJ, Hunt SW. (2000) Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell. J Immunol, 165: 4877-4883. [PMID:11046012]

66. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. (1997) Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med, 185: 99-109. [PMID:8996246]

67. Sato N, Ahuja SK, Quinones M, Kostecki V, Reddick RL, Melby PC, Kuziel WA, Ahuja SS. (2000) CC chemokine receptor (CCR)2 is required for langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, b cell outgrowth, and sustained neutrophilic inflammation. J Exp Med, 192: 205-218. [PMID:10899907]

68. Scott HM, Flynn JL. (2002) Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun, 70: 5946-5954. [PMID:12379669]

69. Siebert H, Sachse A, Kuziel WA, Maeda N, Brück W. (2000) The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol, 110: 177-185. [PMID:11024548]

70. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, O'Brien SJ. (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science, 277: 959-965. [PMID:9252328]

71. Stein O, Dabach Y, Ben-Naim M, Halperin G, Charo IF, Stein Y. (2003) In CCR2-/- mice monocyte recruitment and egress of LDL cholesterol in vivo is impaired. Biochem Biophys Res Commun, 300: 477-481. [PMID:12504109]

72. Su B, Sun G, Lu D, Xiao J, Hu F, Chakraborty R, Deka R, Jin L. (2000) Distribution of three HIV-1 resistance-conferring polymorphisms (SDF1-3'A, CCR2-641, and CCR5-delta32) in global populations. Eur J Hum Genet, 8: 975-979. [PMID:11175286]

73. Szalai C, Duba J, rohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A. (2001) Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis, 158: 233-239. [PMID:11500196]

74. Tanaka S, Green SR, Quehenberger O. (2002) Differential expression of the isoforms for the monocyte chemoattractant protein-1 receptor, CCR2, in monocytes. Biochem Biophys Res Commun, 290: 73-80. [PMID:11779135]

75. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB. (2000) CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J Immunol, 164: 2021-2027. [PMID:10657654]

76. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA. (1997) High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest, 100: 1137-1143. [PMID:9276730]

77. Valdes AM, Wolfe ML, O'Brien EJ, Spurr NK, Gefter W, Rut A, Groot PH, Rader DJ. (2002) Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol, 22: 1924-1928. [PMID:12426226]

78. Warmington KS, Boring L, Ruth JH, Sonstein J, Hogaboam CM, Curtis JL, Kunkel SL, Charo IR, Chensue SW. (1999) Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen-elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses. Am J Pathol, 154: 1407-1416. [PMID:10329593]

79. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest, 116: 115-124. [PMID:16341265]

80. Wisniewski T, Bayne E, Flanagan J, Shao Q, Wnek R, Matheravidathu S, Fischer P, Forrest MJ, Peterson L, Song X et al.. (2010) Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J. Immunol. Methods, 352 (1-2): 101-10. [PMID:19913021]

81. Wong LM, Myers SJ, Tsou CL, Gosling J, Arai H, Charo IF. (1997) Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem, 272: 1038-1045. [PMID:8995400]

82. Xue CB, Feng H, Cao G, Huang T, Glenn J, Anand R, Meloni D, Zhang K, Kong L, Wang A et al.. (2011) Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist. ACS Med Chem Lett, 2 (6): 450-4. [PMID:24900329]

83. Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K et al.. (2011) Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist. ACS Med Chem Lett, 2 (12): 913-8. [PMID:24900280]

84. Yamada Y, Ando F, Niino N, Shimokata H. (2002) Association of a polymorphism of the CC chemokine receptor-2 gene with bone mineral density. Genomics, 80: 8-12. [PMID:12079277]

85. Yang X, Lu P, Ishida Y, Kuziel WA, Fujii C, Mukaida N. (2006) Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization. Int J Cancer, 118: 335-345. [PMID:16052523]

86. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. (2004) Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet, 41: e59-e59. [PMID:15121787]

87. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schröppel B, Rees AJ, Weber C. (2001) Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol, 166: 5755-5762. [PMID:11313419]

88. Zheng Y, Qin L, Zacarías NV, de Vries H, Han GW, Gustavsson M, Dabros M, Zhao C, Cherney RJ, Carter P et al.. (2016) Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature, 540 (7633): 458-461. [PMID:27926736]

89. Zou D, Dasse O, Evans J, Higgins P, Kintigh J, Kondru R, Schwartz E, Knerr L, Zhai H-X. (2005) Pyrrolidinone derivatives. Patent number: US6936633. Assignee: Ucb S.A.. Priority date: 03/10/2001. Publication date: 20/08/2005.

Contributors

Show »

How to cite this page

Israel F. Charo, Rebecca Hills, Richard Horuk, Kouji Matsushima, Philip M. Murphy, Joost J. Oppenheim.
Chemokine receptors: CCR2. Last modified on 26/06/2018. Accessed on 19/11/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59.